Skip to Main Content
Try STAT+ TODAY
Trending:
First Opinion
Health Tech
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

  • Adam Feuerstein

By Adam Feuerstein April 13, 2020

Reprints
Biotech in the time of corona
Mike Reddy/STAT

Seeing the Easter Bunny wear a mask was weird. Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: When will biotech M&A return? Did Sage Therapeutics CEO take a pay cut? Biotech in an America First world; and more chatter about #JPM21.

What will it take for mergers and acquisitions to return to biotech?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

If you think health care is dysfunctional now, just…
If you think health care is dysfunctional now, just wait until after January 1
Limits of ‘Fauci effect’: infectious disease applicants plummet, and…
Limits of ‘Fauci effect’: infectious disease applicants plummet, and hospitals are scrambling
Eli Lilly tightens access to diabetes drug, frustrating some…
Eli Lilly tightens access to diabetes drug, frustrating some people with obesity
The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a…
The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing
Medicare chief: ‘Door is really open’ on coverage for…
Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug
Pharmalittle: Mark Cuban’s drug company goes after employer market;…
Pharmalittle: Mark Cuban’s drug company goes after employer market; FDA slaps import alert on key Sun…

Recommended Stories